- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 1st, 2009
Nanotechnology firm Liquidia Technologies has closed on just a bit more than $7 million in new financing.
According to a filing with the Securities and Exchange Commission, Liquidia raised $7,031,130 in equity funding on July 15.
Neal Fowler, the company's chief executive officer, told the Triangle Business Journal that the new funds would be used for drug design and delivery.
Its first target is a vaccine, which Liquidia hopes to have in clinical trials by late 2010, the newspaper reported.
Several pharmaceutical firms have already licensed Liquidia technology for drug development, according to Fowler.
In January, Liquidia announced a partnership with Abbott to develop means of delivering drugs through nanotechnology..
Liquidia has developed a nanotechnology program called PRINT. The process uses nanotechnology to produce thin films that can be used for light management and other uses.
|Related News Press|
News and information
Kalam: versatility personified August 1st, 2015
Gold-diamond nanodevice for hyperlocalised cancer therapy: Gold nanorods can be used as remote controlled nanoheaters delivering the right amount of thermal treatment to cancer cells, thanks to diamond nanocrystals used as temperature sensors August 1st, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015